Cigna Corp. rose$. 65 or. 8 percent, to $87.15. Humana Inc. rose$. 42 or. 4 percent, to $104.42. UnitedHealth Group rose$. 22 or. 3 percent, to $73.72.» Read More
It’s rare for the world's leading pharmaceutical companies and other partners to work together to tackle an urgent global health issue. It’s time for this to change and our new coordinated effort – unlike previous siloed, disease-by-disease approaches – is the first step.
Employees enrolled in at-work wellness programs report reduced personal healthcare costs, according to a new study, and their employers, who are seeing higher productivity and attendance, are often happy to foot the bill.
Expecting Aetna and UnitedHealth to beat Wall Street estimates as health insurers kick off fourth-quarter earnings, senior analyst Peter Costa of Wells Fargo says these companies will continue their winning streak in 2012, due to rising costs, lower unemployment and even health-care reform.
After some lean times in 2009, Weight Watchers decided to "take destiny by the horns" and become more aggressive in getting the overweight to lose pounds using its program.
In court papers filed Friday, accused ponzi schemer Allen Stanford's court-appointed attorney said he will call on two neurologists, a neuropsychologist, a forensic psychiatrist, a medical doctor and a staff psychiatrist to testify at a hearing on whether Stanford is competent to stand trial.
Is legislated healthcare reform here to stay? As we watch the presidential race heat up – and look to a Supreme Court ruling this summer — no one knows for sure. Regardless, we as a nation need to realize that traditional thinking around healthcare is forever changed.
The US economy is now taking a bite out of dentist office sales, with Lawrence Marsh, Barclays Capital sr. research analyst.
Here's how the "Fast Money" traders play to approach yet another day of trading.
The market is always too optimistic about firms under DOJ fraud investigation, says Sheryl Skolnick, CRT Capital healthcare analyst. Checking in on health care, with CNBC's Herb Greenberg.
As healthcare provider WhiteGlove Health readies for another attempt to price its initial public offering this week, industry experts are skeptical that the firm will be able to attract investors.
While some people are frustrated about the long wait times for doctors appointments, some believe doctors are doing their jobs.
Medicare and Medicaid are often confused with each other as both are government sponsored health programs. But there are major differences. CNBC explains.
Kieren Gallahue, the new CEO of CareFusion, discusses what's behind CareFusion stock's 13% growth rate.
The Centers for Disease Control considers obesity in America an epidemic; more than one out of three adults and 17 percent of all children are technically overweight to the point of obesity.
Spending a month in China earlier this year left me with a clear picture of a nation of rapid change, vast scale, and stark contrasts. All of these factors create opportunities – and challenges – for American businesses in China, and particularly for those of us in health care.
Personalized medicine has finally arrived and is poised to deliver significant health improvement and healthcare cost savings.
The government is making an increasing number of expensive life-saving or life extending drugs and devices available to more people, but is that the right thing to do and can we afford it, anyway?
Health care is an emotional subject for many Americans — and often one of extremes. Yet, as we obssess about the system's structure and cost, we neglect our own health. Obesity and high blood pressure are more common, while exercise and diet are overlooked. Our special report, "Healthy Business", explores these issues.
More and more American women are seeking infertility treatment to increase their chances of having a child, but there's been no change in success rates and costs remain high, even with health insurance coverage.
Expected government cuts to Medicare and Medicaid, the uncertainty of health care reform and looming patent expirations are weighing heavily on the outlook of the biggest companies in the sector: large-cap pharmaceutical stocks.